Search Results

Synedgen, Inc. announced it has completed IND-enabling studies for its lead candidate, MIIST305.

Synedgen, a biopharma company dedicated to using its Multivalent Innate Immune Signaling Target (MIIST) platform to develop drugs that mimic and enhance the innate immune system, today announced that industry veteran Dennis Fenton, Ph.D., has joined Synedgen’s Board of Directors.

Synedgen’s CEO, Shenda Baker, gave a related keynote lecture at the Pan Pacific Connective Tissue Societies Symposium on November 25, 2020

Synedgen, a biotechnology company using glycopolymer chemistry to develop therapeutics that enhance and control signaling in the innate immune system, today announced the initiation of a randomized controlled trial (RCT) to test the safety and effectiveness of SynePure™ Wound Cleanser (SynePure) in combination with Catasyn™ Advanced Technology Hydrogel (Catasyn) for the treatment of superficial partial-thickness burn wounds.

Synedgen, a biotechnology company using glycochemistry to develop drugs that enhance and mimic the innate immune system, today announced the award of a new patent by the European Patent Office (EPO), covering aspects of the treatment of mucositis in the gastrointestinal (GI) tract with Synedgen’s glycopolymer platform of molecules (EP 2555760).

Synedgen, a biotechnology company using glycochemistry to develop drugs that enhance and mimic the innate immune system, today announced that it has received $2.6 million in private financing to fund the commercialization of Catasyn™ Advanced Technology Wound Hydrogel and SynePure™ Wound Cleanser, two U. S. Food and Drug Administration (FDA) 510(k)-cleared products that form part of Synedgen’s Wound Care portfolio.